<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jeong JH</submitter><funding>Korea Health Industry Development Institute</funding><funding>Ministry of Health and Welfare</funding><pagination>562-569</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9622308</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>30(6)</volume><pubmed_abstract>Etretinate, an acitretin metabolite, has a long retention duration in adipose tissues with a teratogenic potential. FDA advises a contraceptive period of at least three years after discontinuing acitretin. However, the effect of accumulated etretinate in adipose tissues on fetus is unknown. Although the teratogenic threshold for serum concentration of etretinate has been presented as higher than 2 ng/mL, that of acitretin is unknown. To examine factors affecting body retention of acitretin and etretinate, effects of acitretin dosage, acitretin-taking duration, elapsed time after stopping acitretin, age, sex, concomitant alcohol consumption, and foods and supplements rich in vitamin A intake on serum concentrations of acitretin and etretinate were analyzed in 14 acitretin-taken patients and</pubmed_abstract><journal>Biomolecules &amp; therapeutics</journal><pubmed_title>Clinical Factors Affecting the Serum Retention of a Teratogenic Etretinate after the Acitretin Administration.</pubmed_title><pmcid>PMC9622308</pmcid><funding_grant_id>HP20C0131</funding_grant_id><pubmed_authors>Lee AY</pubmed_authors><pubmed_authors>Jeong JH</pubmed_authors><pubmed_authors>Park YJ</pubmed_authors><pubmed_authors>Hyun GH</pubmed_authors><pubmed_authors>Kwon SW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical Factors Affecting the Serum Retention of a Teratogenic Etretinate after the Acitretin Administration.</name><description>Etretinate, an acitretin metabolite, has a long retention duration in adipose tissues with a teratogenic potential. FDA advises a contraceptive period of at least three years after discontinuing acitretin. However, the effect of accumulated etretinate in adipose tissues on fetus is unknown. Although the teratogenic threshold for serum concentration of etretinate has been presented as higher than 2 ng/mL, that of acitretin is unknown. To examine factors affecting body retention of acitretin and etretinate, effects of acitretin dosage, acitretin-taking duration, elapsed time after stopping acitretin, age, sex, concomitant alcohol consumption, and foods and supplements rich in vitamin A intake on serum concentrations of acitretin and etretinate were analyzed in 14 acitretin-taken patients and</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-06-01T00:32:41.71Z</modification><creation>2025-06-01T00:32:41.71Z</creation></dates><accession>S-EPMC9622308</accession><cross_references><pubmed>35871607</pubmed><doi>10.4062/biomolther.2022.069</doi></cross_references></HashMap>